desipramine has been researched along with Cell Transformation, Neoplastic in 2 studies
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
Cell Transformation, Neoplastic: Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Incubation for 48 hours of C6 glioma cell cultures with 10(-4)M tricyclic antidepressant desipramine gave rise to a quantitative increase of total lipids and to qualitative modifications of glycosphinegolipids involving detection by thin-layer chromatography of spots migrating according to cerebroside and sulfatide and presence of an abnormal ganglioside pattern." | 7.66 | Tricyclic antidepressant desipramine induces stereospecific opiate binding and lipid modifications in rat glioma C6 cells. ( Albouz, S; Baumann, N; Bourdon, R; Boutry, JM; Hauw, JJ; Le Saux, F; Tocqué, B, 1982) |
| "Incubation for 48 hours of C6 glioma cell cultures with 10(-4)M tricyclic antidepressant desipramine gave rise to a quantitative increase of total lipids and to qualitative modifications of glycosphinegolipids involving detection by thin-layer chromatography of spots migrating according to cerebroside and sulfatide and presence of an abnormal ganglioside pattern." | 3.66 | Tricyclic antidepressant desipramine induces stereospecific opiate binding and lipid modifications in rat glioma C6 cells. ( Albouz, S; Baumann, N; Bourdon, R; Boutry, JM; Hauw, JJ; Le Saux, F; Tocqué, B, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kinjo, T | 1 |
| Kowalczyk, P | 1 |
| Kowalczyk, M | 1 |
| Walaszek, Z | 1 |
| Nishimaki, T | 1 |
| Slaga, TJ | 1 |
| Hanausek, M | 1 |
| Albouz, S | 1 |
| Tocqué, B | 1 |
| Hauw, JJ | 1 |
| Boutry, JM | 1 |
| Le Saux, F | 1 |
| Bourdon, R | 1 |
| Baumann, N | 1 |
2 other studies available for desipramine and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
Desipramine inhibits the growth of a mouse skin squamous cell carcinoma cell line and affects glucocorticoid receptor-mediated transcription.
Topics: Animals; Anti-Inflammatory Agents; Antidepressive Agents, Tricyclic; Blotting, Western; Carcinoma, S | 2009 |
Tricyclic antidepressant desipramine induces stereospecific opiate binding and lipid modifications in rat glioma C6 cells.
Topics: Animals; Cell Transformation, Neoplastic; Desipramine; Dihydromorphine; Glioma; Lipid Metabolism; Ne | 1982 |